Q1 EPS Forecast for Twist Bioscience Increased by Analyst

Twist Bioscience Co. (NASDAQ:TWST - Free Report) - Equities researchers at William Blair lifted their Q1 2025 earnings per share (EPS) estimates for shares of Twist Bioscience in a research report issued to clients and investors on Monday, November 18th. William Blair analyst M. Larew now forecasts that the company will post earnings per share of ($0.58) for the quarter, up from their prior forecast of ($0.72). The consensus estimate for Twist Bioscience's current full-year earnings is ($2.56) per share. William Blair also issued estimates for Twist Bioscience's Q2 2025 earnings at ($0.57) EPS, Q3 2025 earnings at ($0.53) EPS, Q4 2025 earnings at ($0.44) EPS and FY2025 earnings at ($2.11) EPS.

A number of other brokerages have also commented on TWST. JPMorgan Chase & Co. upped their target price on Twist Bioscience from $28.00 to $35.00 and gave the company an "underweight" rating in a research note on Monday, August 5th. Scotiabank upped their target price on shares of Twist Bioscience from $50.00 to $54.00 and gave the company a "sector outperform" rating in a research report on Tuesday. Barclays reduced their price target on Twist Bioscience from $55.00 to $52.00 and set an "overweight" rating for the company in a research report on Tuesday. Leerink Partners increased their target price on shares of Twist Bioscience from $45.00 to $48.00 and gave the stock a "market perform" rating in a report on Thursday, October 17th. Finally, Robert W. Baird increased their price objective on Twist Bioscience from $46.00 to $48.00 and gave the company an "outperform" rating in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat.com, Twist Bioscience presently has a consensus rating of "Moderate Buy" and an average target price of $51.78.

Twist Bioscience Price Performance

NASDAQ:TWST traded up $1.11 during midday trading on Thursday, reaching $42.22. The stock had a trading volume of 526,378 shares, compared to its average volume of 950,996. Twist Bioscience has a 1-year low of $23.07 and a 1-year high of $60.90. The stock has a market capitalization of $2.51 billion, a P/E ratio of -11.42 and a beta of 1.78. The firm's fifty day simple moving average is $43.93 and its 200-day simple moving average is $46.15.

Institutional Investors Weigh In On Twist Bioscience

Several large investors have recently modified their holdings of TWST. American International Group Inc. lifted its position in shares of Twist Bioscience by 0.8% during the first quarter. American International Group Inc. now owns 28,506 shares of the company's stock worth $978,000 after acquiring an additional 213 shares in the last quarter. Caprock Group LLC grew its holdings in Twist Bioscience by 2.9% during the 2nd quarter. Caprock Group LLC now owns 7,851 shares of the company's stock valued at $387,000 after buying an additional 220 shares in the last quarter. Signaturefd LLC increased its position in shares of Twist Bioscience by 63.0% during the third quarter. Signaturefd LLC now owns 792 shares of the company's stock valued at $36,000 after buying an additional 306 shares during the period. Arizona State Retirement System boosted its position in shares of Twist Bioscience by 1.9% in the second quarter. Arizona State Retirement System now owns 16,187 shares of the company's stock valued at $798,000 after acquiring an additional 308 shares during the period. Finally, Massachusetts Financial Services Co. MA boosted its holdings in Twist Bioscience by 3.5% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 9,279 shares of the company's stock valued at $457,000 after purchasing an additional 312 shares during the period.

Insider Transactions at Twist Bioscience

In other news, SVP Paula Green sold 1,057 shares of the business's stock in a transaction that occurred on Monday, November 4th. The stock was sold at an average price of $41.56, for a total value of $43,928.92. Following the transaction, the senior vice president now owns 121,013 shares in the company, valued at $5,029,300.28. The trade was a 0.87 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Emily M. Leproust sold 14,334 shares of Twist Bioscience stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $44.60, for a total value of $639,296.40. Following the sale, the chief executive officer now owns 589,552 shares in the company, valued at $26,294,019.20. This trade represents a 2.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 98,118 shares of company stock valued at $4,391,151 over the last ninety days. 3.92% of the stock is owned by company insiders.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.